

- Guo Y-K, Yang Z-G, Li Y, et al. Uncommon adrenal masses: CT and MRI features with histopathologic correlation. *Eur J Radiol* 2007;62:359–370.
- Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. *Clin Endocrinol (Oxf)* 2002;56:1–7.
- Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. *Endocr Rev* 1995;16:460–484.
- Yang Z-G, Guo Y-K, Li Y, et al. Differentiation between tuberculosis and primary tumors in the adrenal gland: evaluation with contrast-enhanced CT. *Eur Radiol* 2006;16:2031–2036.
- Koene RJ, Catanese J, Sarosi GA. Adrenal hypofunction from histoplasmosis: a literature review from 1971 to 2012. *Infection* 2013;41:757–759.
- Young WF. Clinical practice. The incidentally discovered adrenal mass. *N Engl J Med* 2007;356:601–610.
- Nieman LK. Approach to the patient with an adrenal incidentaloma. *J Clin Endocrinol Metab* 2010;95:4106–4113.
- Malendowicz LK. 100th anniversary of the discovery of the human adrenal fetal zone by Stella Starkel and Leslaw Węgrzynowski: how far have we come? *Folia Histochem Cytobiol* 2010;48:491–506.
- Miller BS, Doherty GM. Regional lymphadenectomy for adrenocortical carcinoma. *Ann Surg* 2013;257:e13–e14.
- Kahraman D, Goretzki PE, Szangolies M, et al. Extra-adrenal pheochromocytoma in the organ of Zuckerkandl: diagnosis and treatment strategies. *Exp Clin Endocrinol Diabetes* 2011;119:436–439.
- Anderson JK, Cadeddu JA. *Surgical Anatomy of the Retroperitoneum, Adrenals, Kidneys, and Ureters*. 10th ed. Amsterdam: Elsevier Inc.; 2012.
- Stewart PM, Krone NP. The adrenal cortex. In: Melmed S, Polonsky KS, Larsen R, et al, eds. *Williams Textbook of Endocrinology*. 12th ed. Amsterdam: Elsevier Inc.; 2011:479–544.
- Young WF Jr. Endocrine hypertension. In: Melmed S, Polonsky KS, Larsen R, et al, eds. *Williams Textbook of Endocrinology*. 12th ed. Amsterdam: Elsevier Inc.; 2011:545–577.
- Arnaldi G, Boscaro M. Adrenal incidentaloma. *Best Pract Res Clin Endocrinol Metab* 2012;26:405–419.
- Stratakis CA. New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors. *Mol Cell Endocrinol* 2009;300:152–157.
- Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol* 2006;48:2293–2300.
- Bernard M-H, Sidhu S, Berger N, et al. A case report in favor of a multistep adrenocortical tumorigenesis. *J Clin Endocrinol Metab* 2003;88:998–1001.
- Ronchi CL, Sbiera S, Leich E, et al. Single nucleotide polymorphism array profiling of adrenocortical tumors—evidence for an adenoma carcinoma sequence? *PLoS ONE* 2013;8:e73959.
- Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β -catenin. *Am J Pathol* 2012;181:1017–1033.
- Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. *Eur J Endocrinol* 2013;169:891–899.
- Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. *J Clin Endocrinol Metab* 2011;96:3775–3784.
- Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. *World J Surg* 2001;25:891–897.
- Foo SH, Chan SP, Ananda V, et al. Dopamine-secreting pheochromocytomas and paragangliomas: clinical features and management. *Singapore Med J* 2010;51:e89–e93.
- Goodall M, Stone C. Adrenaline and noradrenaline producing tumors of the adrenal medulla and sympathetic nerves. *Ann Surg* 1960;151:391–398.
- Crout JR, Sjoerdsma A. Turnover and metabolism of catecholamines in patients with pheochromocytoma. *J Clin Invest* 1964;43:94–102.
- Parenti G, Zampetti B, Rapizzi E, et al. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. *J Oncol* 2012;2012:872713.
- Eisenhofer G, Keiser H, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. *J Clin Endocrinol Metab* 1998;83:2175–2185.
- Coffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. *J Surg Oncol* 2013;107:659–664.
- Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. *Nat Clin Pract Endocrinol Metab* 2007;3:92–102.
- Cimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. *Horm Metab Res* 2012;44:328–333.
- Riccardi VM, Lewis RA. Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants. *Am J Hum Genet* 1988;42:284–289.
- Maier ER, Iselius L, Yates JR, et al. Von Hippel-Lindau disease: a genetic study. *J Med Genet* 1991;28:443–447.
- Nieman S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. *Nat Genet* 2000;26:268–270.
- Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. *Science* 2009;325:1139–1142.
- Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. *Nat Genet* 2011;43:663–667.
- Astuti D, Laitf F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. *Am J Hum Genet* 2001;69:49–54.
- Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. *Science* 2000;287:848–851.
- Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. *Nat Genet* 2010;42:229–233.
- Nieman S, Steinberger D, Müller U. PGL3, a third, not maternally imprinted locus in autosomal dominant paraganglioma. *Neurogenetics* 1999;2:167–170.
- Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. *Mol Cell Endocrinol* 2012;351:66–70.
- Burnichon N, Brière JJ, Libé R, et al. SDHA is a tumor suppressor gene causing paraganglioma. *Hum Mol Genet* 2010;19:3011–3020.
- Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. *Am J Pathol* 2003;162:521–531.
- Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. *Mol Cell Endocrinol* 2014;386:67–84.
- Choi M, Scholl UI, Yue P, et al. K⁺ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science* 2011;331:768–772.
- Azizan EAB, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. *Nat Genet* 2013;45:1055–1060.
- Åkerström T, Crona J, Delgado Verdugo A, et al. Comprehensive resequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. *PLoS ONE* 2012;7(7):e41926.
- Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. *Nat Genet* 2013;45:440–444, 444e1–444e2.
- Gicquel C, Raffin-Sanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. *J Clin Endocrinol Metab* 1997;82:2559–2565.
- Eisenhofer G, Vocke CD, Elkahoul A, et al. Genetic screening for von Hippel-Lindau gene mutations in non-syndromic pheochromocytoma: low prevalence and false-positives or misdiagnosis indicate a need for caution. *Horm Metab Res* 2012;44:343–348.
- Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. *J Clin Endocrinol Metab* 2009;94:2817–2827.
- Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. *J Endocrinol Invest* 2006;29:298–302.
- Singh PK, Buch HN. Adrenal incidentaloma: evaluation and management. *J Clin Pathol* 2008;61:1168–1173.
- Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. *J Clin Endocrinol Metab* 2006;91:2027–2037.
- Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? *World J Surg* 2006;30:872–878.
- Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. *Cancer* 2008;113:3130–3136.
- Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. *Cancer* 1993;72:3145–3155.
- Hsing AW, Nam JM, Co Chien HT, et al. Risk factors for adrenal cancer: an exploratory study. *Int J Cancer* 1996;65:432–436.
- Sirrianni R, Zolea F, Chimento A, et al. Targeting estrogen receptor-alpha reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. *J Clin Endocrinol Metab* 2012;97:E2238–E2250.
- Raymond VM, Else T, Everett JN, et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. *J Clin Endocrinol Metab* 2013;98:E119–E125.
- Raymond VM, Everett JN, Furtado LV, et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. *J Clin Oncol* 2013;31:3012–3018.

61. Sutton MG, Sheps SC, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. *Mayo Clin Proc* 1981;56:354–360.
62. Leung K, Stamm M, Raja A, et al. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. *AJR Am J Roentgenol* 2013;200:370–378.
63. Edström Elder E, Hjeltn Skog A-L, Höög A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. *Eur J Surg Oncol* 2003;29:278–283.
64. Guerrero MA, Schreinemakers JMJ, Vriens MR, et al. Clinical spectrum of pheochromocytoma. *J Am Coll Surg* 2009;209:727–732.
65. Neumann HPH, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. *N Engl J Med* 2002;346:1459–1466.
66. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. *J Clin Oncol* 2009;27:1250–1256.
67. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res* 2003;63:6643–6650.
68. Gatta-Cherifi B, Chabre O, Murat A, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'étude des Tumeurs Endocrines database. *Eur J Endocrinol* 2012;166:269–279.
69. Kinney MAO, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. *J Cardiothorac Vasc Anesth* 2002;16:359–369.
70. Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. *Endocr Rev* 2013;35:282–326.
71. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. *Endocr Relat Cancer* 2005;12:667–680.
72. Berruti A, Baudin E, Gelderblom H, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012;23:viii131–viii138.
73. Lenders JWM, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? *JAMA* 2002;287:1427–1434.
74. Szalat A, Fraenkel M, Doviner V, et al. Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. *Endocrine* 2011;39:160–166.
75. Rao F, Keiser HR, O'Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. *Hypertension* 2000;36:1045–1052.
76. van der Harst E, de Herder WW, de Krijger RR, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. *Eur J Endocrinol* 2002;147:85–94.
77. Low G, Dhaliwayo H, Lomas DJ. Adrenal neoplasms. *Clin Radiol* 2012;67:988–1000.
78. Gust L, Taieb D, Beliard A, et al. Preoperative 18F-FDG uptake is strongly correlated with malignancy, Weiss score, and molecular markers of aggressiveness in adrenal cortical tumors. *World J Surg* 2012;36:1406–1410.
79. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. *Radiology* 2005;234:479–485.
80. Caoili EM, Korobkin M, Francis IR, et al. Delayed enhanced CT of lipid-poor adrenal adenomas. *AJR Am J Roentgenol* 2000;175:1411–1415.
81. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. *Radiology* 2002;222:629–633.
82. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. *AJR Am J Roentgenol* 2002;179:559–568.
83. Groussin L, Bonardel G, Silvéra S, et al. 18F-fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. *J Clin Endocrinol Metab* 2009;94:1713–1722.
84. Caoili EM, Korobkin M, Brown RK, et al. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. *Acad Radiol* 2007;14:468–475.
85. Gross MD, Avram A, Fig LM, et al. PET in the diagnostic evaluation of adrenal tumors. *Q J Nucl Med Mol Imaging* 2007;51:272–283.
86. Elaini AB, Shetty SK, Chapman VM, et al. Improved detection and characterization of adrenal disease with PET-CT. *RadioGraphics* 2007;27:755–767.
87. Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. *J Nucl Med* 2006;47:32–37.
88. Boland GWL, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. *Radiology* 2011;259:117–126.
89. Kim JY, Kim SH, Lee HJ, et al. Utilisation of combined 18F-FDG PET/CT scan for differential diagnosis between benign and malignant adrenal enlargement. *Br J Radiol* 2013;86:20130190.
90. Yun M, Kim W, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. *J Nucl Med* 2001;42:1795–1799.
91. Chong S, Lee KS, Kim HY, et al. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. *Radiographics* 2006;26:1811–1824, discussion 1824–1826.
92. Erasmus JJ, Patz EF, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. *AJR Am J Roentgenol* 1997;168:1357–1360.
93. Kumar R, Xiu Y, Yu JQ, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. *J Nucl Med* 2004;45:2058–2062.
94. Plouin PF, Fitzgerald P, Rich T, et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. *Horm Metab Res* 2012;44:390–399.
95. Taieb D, Timmers HJ, Hindié E, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging* 2012;39:1977–1995.
96. Quayle FJ, Spittle JA, Pierce RA, et al. Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. *Surgery* 2007;142:497–502; discussion 502–504.
97. Paulsen SD, Nghiem HV, Korobkin M, et al. Changing role of imaging-guided percutaneous biopsy of adrenal masses: evaluation of 50 adrenal biopsies. *AJR Am J Roentgenol* 2004;182:1033–1037.
98. Vanderveen KA, Thompson SM, Callstrom MR, et al. Biopsy of pheochromocytomas and paragangliomas: potential for disaster. *Surgery* 2009;146:1158–1166.
99. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. *Am J Surg Pathol* 1984;8:163–169.
100. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. *Am J Surg Pathol* 1989;13:202–206.
101. Assié G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. *J Clin Endocrinol Metab* 2007;92:148–154.
102. Lebastchi AH, Kunstman JW, Carling T. Adrenocortical carcinoma: current therapeutic state-of-the-art. *J Oncol* 2012;2012:234726.
103. Fasnacht M, Johansen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. *Cancer* 2009;115:243–250.
104. Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. *Eur J Cancer* 2010;46:713–719.
105. Miller BS, Gauger PG, Hammer GD, et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. *Langenbecks Arch Surg* 2010;395:955–961.
106. Thompson LDR. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. *Am J Surg Pathol* 2002;26:551–566.
107. Strong VE, Kennedy T, Al-Ahmadie H, et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. *Surgery* 2008;143:759–768.
108. Agarwal A, Mehrotra PK, Jain M, et al. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? *World J Surg* 2010;34:3022–3028.
109. Wu D, Tischler AS, Lloyd RV, et al. Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. *Am J Surg Pathol* 2009;33:599–608.
110. Giavarini A, Chedid A, Bobrie G, et al. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. *Heart* 2013;99:1438–1444.
111. Steinsapir J, Carr AA, Prisant LM, et al. Metyrosine and pheochromocytoma. *Arch Intern Med* 1997;157:901–906.
112. Kinney MA, Warner ME, van Heerden JA, et al. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. *Anesth Analg* 2000;91:1118–1123.
113. Phitayakorn R, McHenry CR. Perioperative considerations in patients with adrenal tumors. *J Surg Oncol* 2012;106:604–610.
114. Prys-Roberts C. Pheochromocytoma—recent progress in its management. *Br J Anaesth* 2000;85:44–57.
115. Bravo EL. Pheochromocytoma: an approach to antihypertensive management. *Ann N Y Acad Sci* 2002;970:1–10.
116. Siddiqi HK, Yang H-Y, Laird AM, et al. Utility of oral nifedipine and magnesium sulfate infusion during preparation and resection of pheochromocytomas. *Surgery* 2012;152:1027–1036.
117. Libé R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. *Endocr Relat Cancer* 2007;14:13–28.
118. Sippel RS, Elaraj DM, Kebebew E, et al. Waiting for change: symptom resolution after adrenalectomy for Cushing's syndrome. *Surgery* 2008;144:1054–1060; discussion 1060–1061.
119. Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. *J Clin Endocrinol Metab* 2011;96:717–725.
120. Mellon MJ, Sundaram CP. Laparoscopic adrenalectomy for pheochromocytoma versus other surgical indications. *JLS* 2008;12:380–384.
121. Gumbs AA, Gagner M. Laparoscopic adrenalectomy. *Best Pract Res Clin Endocrinol Metab* 2006;20:483–499.
122. Lee J, El-Tamer M, Schiffner T, et al. Open and laparoscopic adrenalectomy: analysis of the National Surgical Quality Improvement Program. *J Am Coll Surg* 2008;206:953–959, discussion 959–961.
123. Nigri G, Rosman AS, Petruccianni N, et al. Meta-analysis of trials comparing laparoscopic transperitoneal and retroperitoneal adrenalectomy. *Surgery* 2013;153:111–119.

124. Walz MK, Alesina PF, Wenger FA, et al. Posterior retroperitoneoscopic adrenalectomy—results of 560 procedures in 520 patients. *Surgery* 2006;140:943–948, discussion 948–950.
125. Agaoglu O, Sahin DA, Siperstein A, et al. Selection algorithm for posterior versus lateral approach in laparoscopic adrenalectomy. *Surgery* 2012;151:731–735.
126. Alesina PF, Hinrichs J, Meier B, et al. Minimally invasive cortical-sparing surgery for bilateral pheochromocytomas. *Langenbecks Arch Surg* 2012;397:233–238.
127. Walz MK. Extent of adrenalectomy for adrenal neoplasm: cortical sparing (subtotal) versus total adrenalectomy. *Surg Clin North Am* 2004;84:743–753.
128. Jaspersen KW, Kohlmann W, Gammon A, et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. *Fam Cancer* 2013 (Epub ahead of print).
129. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. *Arch Pathol Lab Med* 2008;132:1272–1284.
130. Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. *J Clin Endocrinol Metab* 2005;90:2110–2116.
131. Santarpia L, Habra MA, Jiménez C. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. *Horm Metab Res* 2009;41:680–686.
132. Scholz T, Eisenhofer G, Pacak K, et al. Clinical review: Current treatment of malignant pheochromocytoma. *J Clin Endocrinol Metab* 2007;92:1217–1225.
133. Miller BS, Doherty GM. The surgical management of adrenocortical tumors. *Nat Rev Endocrinol* 2014;10:282–292.
134. Garcia LJ, Avella DM, Hartman B, et al. Thoracoabdominal incision: a forgotten tool in the management of complex upper gastrointestinal complications. *Am J Surg* 2009;197:e28–e31.
135. Swan RZ, Hanna EM, Sindram D, et al. Adrenocortical carcinoma with intracaval extension to the right atrium: resection on cardiopulmonary bypass. *Ann Surg Oncol* 2012;19:1275.
136. Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. *Ann Surg* 2012;255:363–369.
137. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. *Cancer* 2008;113:3130–3136.
138. Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. *Eur Urol* 2011;60:1055–1065.
139. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. *J Clin Endocrinol Metab* 2013;98:4551–4564.
140. Giubellino A, Sourbier C, Lee M-J, et al. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. *PLoS ONE* 2013;8:e56083.
141. Gonzalez RJ, Tamm EP, Ng C, et al. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. *Surgery* 2007;142:867–875, discussion 867–875.
142. Veysman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. *J Clin Oncol* 2009;27:4619–4629.
143. Sabolch A, Feng M, Griffith K, et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. *Int J Radiat Oncol Biol Phys* 2011;80:1477–1484.
144. Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. *J Clin Endocrinol Metab* 2006;91:4501–4504.
145. Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. *J Clin Endocrinol Metab* 2013;98:192–197.
146. Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. *Cancer* 2009;115:2816–2823.
147. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. *J Clin Oncol* 2002;20:941–950.
148. Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. *Endocr J* 2008;55:49–55.
149. Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. *J Clin Oncol* 2010;28(23):e401–e402, author reply e403.
150. Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? *Clin Endocrinol* 2010;73:561–565.
151. Erdogan I, Deutschbein T, Jurowich C, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. *J Clin Endocrinol Metab* 2013;98:181–191.
152. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. *Ann Surg Oncol* 1999;6:719–726.
153. op den Winkel J, Pfannschmidt J, Muley T, et al. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. *Ann Thorac Surg* 2011;92:1965–1970.
154. Kemp CD, Ripley RT, Mathur A, et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. *Ann Thorac Surg* 2011;92:1195–1200.
155. Datrice NM, Langan RC, Ripley RT, et al. Operative management for recurrent and metastatic adrenocortical carcinoma. *J Surg Oncol* 2012;105:709–713.
156. Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. *Cancer* 2003;97:554–560.
157. Bauditz J, Quinkler M, Wermke W. Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer—a case report and review of the literature. *Exp Clin Endocrinol Diabetes* 2009;117:316–319.
158. Ripley RT, Kemp CD, Davis JL, et al. Liver resection and ablation for metastatic adrenocortical carcinoma. *Ann Surg Oncol* 2011;18:1972–1979.
159. Li S-H, Huang C-H, Ko S-F, et al. Extended survival in a patient with recurrent and metastatic adrenal cortical carcinoma by aggressive transarterial embolization—a case report. *J Surg Oncol* 2005;90:101–105.
160. Soga H, Takenaka A, Ooba T, et al. A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization. *Urol Int* 2009;82:222–226.
161. Thacker PG, Friese JL, Loe M, et al. Embolization of nonliver visceral tumors. *Semin Intervent Radiol* 2009;26:262–269.
162. Auchus R. Pharmacotherapy for hormone excess in adrenocortical carcinoma. In: Hammer G, Else T, eds. *Adrenocortical Carcinoma*. 1st ed. New York: Springer; 2010:383–402.
163. Drake WM, Perry LA, Hinds CJ, et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. *J Clin Endocrinol Metab* 1998;83:3542–3544.
164. Fleseriu M, Biller BMK, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. *J Clin Endocrinol Metab* 2012;97:2039–2049.
165. Bonacci R, Gigliotti A, Baudin E, et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. *Br J Cancer* 1998;78:546–549.
166. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. *Ann Oncol* 2000;11:1281–1287.
167. Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. *Cancer* 2002;94:2333–2343.
168. Baudin E, Docao C, Gicquel C, et al. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. *Ann Oncol* 2002;13:1806–1809.
169. Khan TS, Sundin A, Juhlin C, et al. Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. *Med Oncol* 2004;21:167–177.
170. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. *Endocr Relat Cancer* 2005;12:657–666.
171. Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. *Endocr Relat Cancer* 2010;17:445–453.
172. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. *N Engl J Med* 2012;366:2189–2197.
173. Eisenhofer G, Tischler AS, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. *Endocr Pathol* 2012;23:4–14.
174. Giubellino A, Bullova P, Nölting S, et al. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. *Endocrinology* 2013;154:646–655.
175. Chen CC, Carrasquillo JA. Molecular imaging of adrenal neoplasms. *J Surg Oncol* 2012;106:532–542.
176. Biggar MA, Lennard TWJ. Systematic review of pheochromocytoma in pregnancy. *Br J Surg* 2013;100:182–190.
177. Young WF Jr. Adrenal medulla, catecholamines, and pheochromocytoma. In: Goldman L, Ausiello DA, eds. *Cecil Medicine*. 24th ed. Amsterdam: Elsevier Inc.; 2011:1470–e235–1.
178. Lekarev O, New MI. Adrenal disease in pregnancy. *Best Pract Res Clin Endocrinol Metab* 2011;25:959–973.
179. Webb JC, Bayliss P. Pregnancy complicated by primary aldosteronism. *South Med J* 1997;90:243–245.
180. Nursal TZ, Caliskan K, Ertorer E, et al. Laparoscopic treatment of primary hyperaldosteronism in a pregnant patient. *Can J Surg* 2009;52:E188–E190.
181. Tripto-Shkolnik L, Blumenfeld Z, Bronshtein M, et al. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature. *J Clin Endocrinol Metab* 2013;98:443–447.
182. Ciftci AO, Tanyel FC, Senocak ME, et al. Pheochromocytoma in children. *J Pediatr Surg* 2001;36:447–452.
183. Ludwig AD, Feig DI, Brandt ML, et al. Recent advances in the diagnosis and treatment of pheochromocytoma in children. *Am J Surg* 2007;194:792–796, discussion 796–797.
184. Kim H-Y, Lee HS, Jung S-E, et al. Experience with surgical excision in childhood pheochromocytoma. *J Korean Med Sci* 2004;19:401–406.
185. Pham TH, Moir C, Thompson GB, et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. *Pediatrics* 2006;118:1109–1117.

186. Helouy Y, Muthucumar M, Panabokke G, et al. Minimally invasive adrenalectomy in children. *J Pediatr Surg* 2012;47:415–421.
187. Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. *Horm Metab Res* 2005;37:717–721.
188. Hernandez MR, Shamberger RC, Seefelder C. Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management. *J Clin Anesth* 2009;21:54–56.
189. Rodriguez-Galindo C, Zambetti GP, Ribeiro RC. Adrenocortical cancer in children. In Hammer GD, Else T, eds. *Adrenocortical Carcinoma*. New York: Springer; 2010;467–482.
190. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. *J Clin Oncol* 2004; 22:838–845.
191. de Fraipont F, Atifi El M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. *J Clin Endocrinol Metab* 2005;90:1819–1829.
192. Hanna AM, Pham TH, Askegard-Giesmann JR, et al. Outcome of adrenocortical tumors in children. *J Pediatr Surg* 2008;43:843–849.
193. Tucci S, Martins ACP, Suaid HJ, et al. The impact of tumor stage on prognosis in children with adrenocortical carcinoma. *J Urol* 2005;174:2338–2342, discussion 2342.
194. Pauwels EKJ, Bourguignon M. Cancer induction caused by radiation due to computed tomography: a critical note. *Acta Radiol* 2011;52:767–773.
195. Albert JM. Radiation risk from CT: implications for cancer screening. *AJR Am J Roentgenol* 2013;201:W81–W87.
196. Buffet A, Smati S, Mansuy L, et al. Mosaicism in HIF2A-related polycythaemia-paraganglioma syndrome. *J Clin Endocrinol Metab* 2014;99:E369–E373.
197. Burnichon N, Cascón A, Schiavi F, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. *Clin Cancer Res* 2012; 18:2828–2837.
198. Carney JA. Carney triad. *Front Horm Res* 2013;41:92–110.
199. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. *Am J Med Genet* 2002; 108:132–139.
200. Castro-Vega LJ, Buffet A, de Cubas AA, et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. *Hum Mol Genet* 2014;23:2440–2446.
201. Bayley J-P, Kunst HPM, Cascón A, et al. SDHAF2 mutations in familial and sporadic paraganglioma and pheochromocytoma. *Lancet Oncol* 2010; 11:366–372.
202. Ladrone C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. *N Engl J Med* 2008;359:2685–2692.
203. Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. *Eur J Hum Genet* 2008;16:79–88.
204. Tenorio Jiménez C, Izatt L, Chang F, et al. Carney Stratakis syndrome in a patient with SDHD mutation. *Endocr Pathol* 2012;23:181–186.
205. Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. *Endocr Relat Cancer* 2011;18:R253–R276.
206. Yao L, Schiavi F, Cascón A, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. *JAMA* 2010;304:2611–2619.
207. Yeh I-T, Lenci RE, Qin Y, et al. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. *Hum Genet* 2008; 124:279–285.
208. Zhuang Z, Yang C, Lorenzo F, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. *N Engl J Med* 2012;367: 922–930.
209. van Baars F, Cremers C, van den Broek P, et al. Genetic aspects of non-chromaffin paraganglioma. *Hum Genet* 1982;60:305–309.